INT16263

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 1990
Last Reported 2010
Negated 2
Speculated 2
Reported most in Body
Documents 13
Total Number 15
Disease Relevance 5.24
Pain Relevance 3.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Serpine1) extracellular region (Serpine1)
Anatomy Link Frequency
NAc 2
coronary artery 1
thoracic duct 1
cartilage 1
heart 1
Serpine1 (Mus musculus)
Pain Link Frequency Relevance Heat
Nucleus accumbens 12 98.92 Very High Very High Very High
Morphine 24 98.64 Very High Very High Very High
COX-2 inhibitor 3 98.48 Very High Very High Very High
Dopamine 16 97.96 Very High Very High Very High
Angina 11 97.24 Very High Very High Very High
agonist 9 91.60 High High
antagonist 3 90.96 High High
Central nervous system 2 89.52 High High
Inflammation 33 81.04 Quite High
Pain 1 79.44 Quite High
Disease Link Frequency Relevance Heat
Coronary Artery Disease 17 100.00 Very High Very High Very High
Myocardial Infarction 19 98.44 Very High Very High Very High
Breast Cancer 62 97.96 Very High Very High Very High
Hypothermia 46 97.76 Very High Very High Very High
Cv General 3 Under Development 6 97.24 Very High Very High Very High
Nociception 8 96.24 Very High Very High Very High
Endotoxemia 21 95.96 Very High Very High Very High
Thrombosis 34 95.36 Very High Very High Very High
Pathologic Neovascularization 3 94.52 High High
Heart Disease 4 92.64 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Surprisingly, we previously reported that neither PAI-1 deficiency nor a pharmacological inhibitor of serine proteases directly affect the endothelial cell sprouting from thoracic duct explants in the lymphatic ring assay [29].
Neg (nor) Regulation (affect) of PAI-1 in thoracic duct
1) Confidence 0.45 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2836381 Disease Relevance 0.45 Pain Relevance 0.07
In the present study, we examined the effects of microinjections of plasminogen activator inhibitor-1 (PAI-1), tPA or plasmin into the NAc on morphine-induced dopamine release, hyperlocomotion and anti-nociceptive effects in ICR mice.
Spec (examined) Regulation (effects) of PAI-1 in NAc associated with nociception, nucleus accumbens, dopamine and morphine
2) Confidence 0.43 Published 2005 Journal J. Neurochem. Section Abstract Doc Link 15948318 Disease Relevance 0.17 Pain Relevance 1.20
In the present study, we examined the effects of microinjections of plasminogen activator inhibitor-1 (PAI-1), tPA or plasmin into the NAc on morphine-induced dopamine release, hyperlocomotion and anti-nociceptive effects in ICR mice.
Spec (examined) Regulation (effects) of plasminogen activator inhibitor-1 in NAc associated with nociception, nucleus accumbens, dopamine and morphine
3) Confidence 0.43 Published 2005 Journal J. Neurochem. Section Abstract Doc Link 15948318 Disease Relevance 0.17 Pain Relevance 1.19
This view is supported by the significant increase in circulating PAI-Ag levels at temperatures of 34°C and 31°C versus 37°C in endotoxemic animals, and the most pronounced endothelial expression of PAI-1 during 31°C hypothermia.
Regulation (circulating) of PAI associated with hypothermia
4) Confidence 0.38 Published 2006 Journal Crit Care Section Body Doc Link PMC1751084 Disease Relevance 0.96 Pain Relevance 0
The changes in uPA, PAI-1 and PGE2 were not significant at either dose for pre- or postmenopausal women.
Regulation (changes) of PAI-1
5) Confidence 0.38 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 0 Pain Relevance 0
We identified two aptamers, WT-15 and SM-20, that disrupt the interactions between PAI-1 and heparin, as well as PAI-1 and vitronectin, without affecting the antiprotease activity of PAI-1.
Neg (without) Regulation (affecting) of PAI-1
6) Confidence 0.27 Published 2009 Journal Oligonucleotides Section Abstract Doc Link 19284310 Disease Relevance 0.48 Pain Relevance 0.07
Dynamic change of serum tissue-type plasminogen, activator (t-PA) and PAI activity was studied in 22 cases with acute myocardial infarction (AMI) 11 cases with unstable angina (UA) and 24 healthy persons.
Regulation (change) of PAI associated with angina and myocardial infarction
7) Confidence 0.15 Published 1991 Journal Zhonghua Nei Ke Za Zhi Section Abstract Doc Link 1815876 Disease Relevance 1.09 Pain Relevance 0.24
A similarly inverse relationship has also been shown between androgens and plasminogen activator inhibitor-1 (PAI-1), fibrinogen and other prothrombotic factors [16,17,38], rounding up the cardioprotective effects of endogenous androgens on the major components of the basic risk profile for heart disease.
Regulation (plasminogen) of activator inhibitor-1 in heart associated with heart disease
8) Confidence 0.13 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2693125 Disease Relevance 0.57 Pain Relevance 0.09
Neither drug had an effect on tissue-type plasminogen activator or plasminogen activator inhibitor type 1 (PAI-1).
Regulation (effect) of plasminogen activator inhibitor type 1
9) Confidence 0.13 Published 1994 Journal Eur. J. Clin. Pharmacol. Section Abstract Doc Link 7915237 Disease Relevance 0.17 Pain Relevance 0.14
Increased plasma levels of plasminogen activator inhibitor-1 (PAI-1) have been shown to exist in 40 to 60% of patients with stable coronary artery disease and have been suggested to be responsible for the development of coronary thrombotic complications.
Regulation (responsible) of plasminogen activator inhibitor-1 in coronary artery associated with coronary artery disease
10) Confidence 0.10 Published 1990 Journal Thromb. Haemost. Section Abstract Doc Link 2119522 Disease Relevance 0.94 Pain Relevance 0.44
We carried out experiments to investigate whether the COX-2 inhibitor celecoxib at a dose of either 200 mg bid or 400 mg bid could significantly affect endogenous uPA, PAI-1 or PGE2 production in women at increased risk for breast cancer.
Regulation (affect) of PAI-1 associated with breast cancer and cox-2 inhibitor
11) Confidence 0.10 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 0.17 Pain Relevance 0.05
We first evaluated the change in uPA, PAI-1 and PGE2 concentration in the NAF of each participant after low and high dose celecoxib administration (Table 2).
Regulation (change) of PAI-1
12) Confidence 0.10 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 0 Pain Relevance 0
The most striking was the up-regulation of uPA and PAI-1 mRNA in 4-day rabbits postoperatively at the onset of cartilage degeneration.
Regulation (regulation) of PAI-1 mRNA in cartilage
13) Confidence 0.09 Published 2005 Journal Chin. Med. J. Section Body Doc Link 15978208 Disease Relevance 0.07 Pain Relevance 0
, via Smad pathway, regulates ECM-related proteins, including the profibrotic mediator CTGF [4], [26], the inhibitor of ECM degradation, PAI-1, [27], and the main ECM component Type I Collagen (Col-1) [4].
Regulation (regulates) of PAI-1
14) Confidence 0.09 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2597201 Disease Relevance 0 Pain Relevance 0
The present study was conducted to compare the efficacy, safety, cost-effectiveness and effects on plasminogen activator inhibitor-1 (PAI-1) levels of three LMWHs--enoxaparin, nadroparin and dalteparin.
Regulation (effects) of plasminogen activator inhibitor-1
15) Confidence 0.07 Published 2006 Journal Pharmacology Section Abstract Doc Link 17057417 Disease Relevance 0 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox